EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Bre... (le arrest andapoptosis. MKC-1 arrests mi...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer

Date:9/10/2007

le arrest, and apoptosis. MKC-1 arrests mitosis by inhibiting an intracellular target important in cellular trafficking that has been shown to be involved in cell division. MKC- 1 has been shown to inhibit mitotic spindle formation, prevent chromosome segregation in the M-phase of the cell cycle, and induce apoptosis in multiple cell lines, consistent with a mechanism in which MKC-1 blocks the nuclear uptake of proteins essential to cell replication.

Carolyn F. Sidor, M.D., M.B.A., EntreMed's Vice President and Chief Medical Officer, commented on the results, "MKC-1 is showing good antitumor activity in metastatic breast cancer patients who had failed conventional anthracycline and taxane chemotherapy. In addition, the study has passed a second Data Safety Monitoring Board (DSMB) review without any study modification. This study is an important milestone for our MKC-1 clinical development program as it confirms that MKC-1 does have single-agent activity and is well-tolerated by these advanced breast cancer patients. An additional MKC-1 single-agent study is underway in hematological cancers and a combination study is underway with pemetrexed (Alimta(R)) in non-small cell lung cancer. We plan to evaluate our options for either randomized single- agent or combination studies in breast cancer once this study is complete."

To view the poster presentation, visit the Recent Presentations section of the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also i
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference

Post Your Comments:

Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2 ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3 ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4 Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2 Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3 Within3 Expands into Mobile Applications 2 Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 1 Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 2 Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 3 Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 4 Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 5 Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 1 Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 2 Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 3 Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 4 Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 5 Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 6 Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 1 Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 2 Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 3 Industry Professionals Get Schooled in Real World Oncology Issues at NCCN Academy 12512 4

[0] ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)[0] Boston Scientific Announces Pricing of $2 Billion of Senior Notes [0] Within3 Expands into Mobile Applications

Other Medicine Technology:Reaction to Avandia Warnings Stronger Among Internists Than,Endocrinologists, According to Study by GfK Market Measures 2 Reaction to Avandia Warnings Stronger Among Internists Than,Endocrinologists, According to Study by GfK Market Measures 3 Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy,of BF-200 ALA In Actinic Keratosis 2

Reaction to Avandia Warnings Stronger Among Internists Than,Endocrinologists, According to Study by GfK Market Measures Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy,of BF-200 ALA In Actinic Keratosis

Breaking Medicine News(10 mins):Health News:Traceability Institute Comments on Improving Food Safety System for Consumers at Food and Drug Administration (FDA) and Food Safety and Inspection Service (FSIS) Joint Public Meeting 2 Health News:Pelosi: Lifting the Ban on Federal Funding for Syringe Exchange is a Victory for Science and for Public Health 2 Health News:Molecule Discovery Might Help ALS Patients 2 Health News:Swine Flu Has Infected 1 in 6 Americans: CDC 2 Health News:Swine Flu Has Infected 1 in 6 Americans: CDC 3 Health News:Macomb County Announces New Location for Four Upcoming H1N1 Clinics 2

[1] Traceability Institute Comments on Improving Food Safety System for Consumers at Food and Drug Administration (FDA) and Food Safety and Inspection Service (FSIS) Joint Public Meeting [0] Pelosi: Lifting the Ban on Federal Funding for Syringe Exchange is a Victory for Science and for Public Health [0] Molecule Discovery Might Help ALS Patients [0] Swine Flu Has Infected 1 in 6 Americans: CDC [0] Macomb County Announces New Location for Four Upcoming H1N1 Clinics

Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden Garry W. Rogerson Elected Chairman of the Board of Varian, Inc.Smokers Will Stop for Their Pet's Sake Diseased Heart Valve Replaced Through Small Chest Incision The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders Shaklee Hits the Road with its Infinite Possibilities Tour in New York, NY

Medicine Products:

Hydrophobic Tubing Filter (green-tinted PVC)Clear-Therm Mini™ + Micro Mount with Flextube Clear-Therm®Filta-Therm® with CO₂ Port

EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Bre...(le arrest andapoptosis. MKC-1 arrests mi...),Health